Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 6, 2012, Pages 550-560

  Niemiec, Joanna A ^a   Adamczyk, Agnieszka ^a   Małecki, Krzysztof ^a   Majchrzyk, Kaja ^a   Ryś, Janusz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

early breast cancer subtypes; Ep CAM; Ki 67 LI; MMP 2; MVD

Indexed keywords

CD34 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; GELATINASE A; KI 67 ANTIGEN; P CADHERIN; PROGESTERONE RECEPTOR; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DENSITY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKOCYTE; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR GROWTH;

ANTIGENS, NEOPLASM; CADHERINS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION MOLECULES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870395385     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31824f21af     Document Type: Article

References (55)

1. Tavassoli FA, Devillee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
4. Sølie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-2675.
5. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
6. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
7. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/ basal-like breast carcinomas. Breast Cancer Res. 2007;9,R65:1-11.
8. Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134-145.
9. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007; 38:197-204.
10. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007;13:90-101.
11. Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol. 2007;31:501-508.
12. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol. 2007;20:474-481.
13. Rodríguez-Pinilla SM, Sarrió D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2007;60:1006-1012.
14. Rodríguez-Pinilla SM, Sarrió D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas. Clin Cancer Res. 2006;12: 1533-1539.
15. Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006;95:1334-1341.
16. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10-21.
17. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006;116:261-270.
18. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11:4003-4011.
19. Paredes J, Lopes N, Milanezi F, et al. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 2007;450:73-80.
20. Matos I, Dufloth R, Alvarenga M, et al. P63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688-694.
21. Liu H, Fan Q, Zhang Z, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167-174.
22. Arnes JB, Collett K, Akslen LA. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology. 2008;52:370-380.
23. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res. 2008;14:1368-1376.
24. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502, 40.
25. Niemiec J, Ryś J. Morphological and immunohistochemical characteristics of breast cancer in the light of the new models of carcinogenesis. Pol J Pathol. 2009;3(S1):1-9.
26. Niemiec J, Ryś J. Basal-like breast carcinoma - the entity with specific immunohistichemical chracteristics. Pol J Pathol. 2009;3(S1):36-44.
27. Lerma E, Barnadas A, Prat J. Triple negative breast carcinomas: similarities and differences with basal like carcinomas. Appl Immunohistochem Mol Morphol. 2009;17:483-494.
28. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11:S37-S43.
29. Winter MJ, Nagtegaal ID, van Krieken JH, et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163:2139-2148.
30. Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005;69:478-485.
31. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671.
32. Jarasch ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988;19:276-289.
33. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996.
34. Perou CM, Sølie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
35. Bankfalvi A, Ludwig A, De-Hesselle B, et al. Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod Pathol. 2004;17:1051-1061.
36. Moinfar F, Man YG, Lininger RA, et al. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasiaductal type - benign and malignant intraductal proliferations. Am J Surg Pathol. 1999;23:1048-1058.
37. Otterbach F, Bànkfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37:232-240.
38. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch. 2003;442:548-554.
39. Rabban JT, Koerner FC, Lerwill MF. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol. 2006;37:787-793.
40. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol. 2002;198:458-467.
41. Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10,R53:1-12.
42. Spizzo G, Obrist P, Ensinger C, et al. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer. 2002;98:883-888.
43. Cohen AW, Carbajal JM, Schaeffer RC Jr. VEGF stimulates tyrosine phosphorylation of beta-catenin and small-pore endothelial barrier dysfunction. Am J Physiol. 1999;277:H2038-H2049.
44. Faratian D, Munro A, Twelves C, et al. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology. 2009;54: 254-257.
45. Soini Y, Hurskainen T, HöyhtyäM, et al. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem. 1994;42:945-951.
46. Brummer O, Athar S, Riethdorf L, et al. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch. 1999;435:566-573.
47. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004;10:7621-7628.
48. Nakopoulou L, Tsirmpa I, Alexandrou P, et al. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat. 2003;77:145-155.
49. Talvensaari-Mattila A, PääkköP, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89:1270-1275.
50. González LO, Corte MD, Junquera S, et al. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol. 2009;40:1224-1233.
51. Lee JS, Kim HS, Jung JJ, et al. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. Appl Immunohistochem Mol Morphol. 2002;10:289-295.
52. Qin Li L, Huang HL, Ping JL, et al. Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS. 2011;119:103-110.
53. Lopes N, Sousa B, Vieira D, et al. Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology. 2009;55:594-599.
54. Raica M, Cimpean AM, Ceausu R, et al. Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in different molecular types of breast cancer. Anticancer Res. 2011;31:1757-1764.
55. Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71-81.